Ginkgo Bioworks (DNA) announced a collaboration with Pfizer (PFE) focused on the discovery of RNA-based drug candidates. In the collaboration, Pfizer will leverage Ginkgo’s proprietary RNA technology to advance the discovery and development of novel RNA molecules across priority research areas. Ginkgo will receive an upfront payment and is eligible to receive research fees and development and commercial milestone payments, up to an aggregate total of $331M across three programs. Ginkgo is entitled to potential further downstream value in the form of royalties on sales.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on DNA:
- Unusually active option classes on open September 27th
- Ginkgo Bioworks, Madagascar enter MoU to develop new biosecurity capabilities
- Cathie Wood’s ARK Investment bought 1.3M shares of Ginkgo Bioworks today
- Cathie Wood’s ARK Investment bought 2.17M shares of Ginkgo Bioworks today
- Cathie Wood’s ARK Investment bought 970K shares of Ginkgo Bioworks today